Cargando…

DNA methylation-driven genes for constructing diagnostic, prognostic, and recurrence models for hepatocellular carcinoma

In this study, we performed a comprehensively analysis of gene expression and DNA methylation data to establish diagnostic, prognostic, and recurrence models for hepatocellular carcinoma (HCC). Methods: We collected gene expression and DNA methylation datasets for over 1,200 clinical samples. Integr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Long, Junyu, Chen, Peipei, Lin, Jianzhen, Bai, Yi, Yang, Xu, Bian, Jin, Lin, Yu, Wang, Dongxu, Yang, Xiaobo, Zheng, Yongchang, Sang, Xinting, Zhao, Haitao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ivyspring International Publisher 2019
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6831284/ https://www.ncbi.nlm.nih.gov/pubmed/31695766 http://dx.doi.org/10.7150/thno.31155

Ejemplares similares

Construction and comprehensive analysis of a ceRNA network to reveal potential prognostic biomarkers for hepatocellular carcinoma
por: Long, Junyu, et al.
Publicado: (2019)

Construction and validation of a prognostic signature using CNV-driven genes for hepatocellular carcinoma
por: Bian, Jin, et al.
Publicado: (2021)

The diagnostic and prognostic role of RhoA in hepatocellular carcinoma
por: Bai, Yi, et al.
Publicado: (2019)

Development and validation of a TP53-associated immune prognostic model for hepatocellular carcinoma
por: Long, Junyu, et al.
Publicado: (2019)

Comparing the efficacy and safety of second-line therapies for advanced hepatocellular carcinoma: a network meta-analysis of phase III trials
por: Wang, Dongxu, et al.
Publicado: (2020)

Identification of hub genes involved in the development of hepatocellular carcinoma by transcriptome sequencing
por: Zheng, Yongchang, et al.
Publicado: (2017)

Combination regimens with PD-1/PD-L1 immune checkpoint inhibitors for gastrointestinal malignancies
por: Wang, Dongxu, et al.
Publicado: (2019)

Comprehensive analysis of a ceRNA network reveals potential prognostic cytoplasmic lncRNAs involved in HCC progression
por: Bai, Yi, et al.
Publicado: (2019)

Targeted Next-Generation Sequencing Combined With Circulating-Free DNA Deciphers Spatial Heterogeneity of Resected Multifocal Hepatocellular Carcinoma
por: Lin, Jianzhen, et al.
Publicado: (2021)

Apatinib as non-first-line treatment in patients with Intrahepatic Cholangiocarcinoma
por: Mao, Jinzhu, et al.
Publicado: (2021)

A mutation-based gene set predicts survival benefit after immunotherapy across multiple cancers and reveals the immune response landscape
por: Long, Junyu, et al.
Publicado: (2022)

Differentially expressed liver exosome-related genes as candidate prognostic biomarkers for hepatocellular carcinoma
por: Zuo, Bangyou, et al.
Publicado: (2022)

A four‐gene‐based prognostic model predicts overall survival in patients with hepatocellular carcinoma
por: Long, Junyu, et al.
Publicado: (2018)

Combination treatment including targeted therapy for advanced hepatocellular carcinoma
por: Lin, Jianzhen, et al.
Publicado: (2016)

The fusion landscape of hepatocellular carcinoma
por: Zhu, Chengpei, et al.
Publicado: (2019)

The Efficacy and Safety of Apatinib Plus Camrelizumab in Patients With Previously Treated Advanced Biliary Tract Cancer: A Prospective Clinical Study
por: Wang, Dongxu, et al.
Publicado: (2021)

Classification of gallbladder cancer by assessment of CD8(+) TIL and PD-L1 expression
por: Lin, Jianzhen, et al.
Publicado: (2018)

Real-world efficacy and prognostic factors of lenvatinib plus PD-1 inhibitors in 378 unresectable hepatocellular carcinoma patients
por: Yang, Xu, et al.
Publicado: (2023)

PD-1/PD-L blockade in gastrointestinal cancers: lessons learned and the road toward precision immunotherapy
por: Long, Junyu, et al.
Publicado: (2017)

Identification and Validation of Constructing the Prognostic Model With Four DNA Methylation-Driven Genes in Pancreatic Cancer
por: Chen, Guangyu, et al.
Publicado: (2022)

Identification of TMB, CD8 T‐cell abundance, and homologous repair pathway mutation frequency as predictors of the benefit–toxicity ratio of anti‐PD‐1/PD‐L1 therapy
por: Long, Junyu, et al.
Publicado: (2021)

Cell-free DNA copy number variations predict efficacy of immune checkpoint inhibitor-based therapy in hepatobiliary cancers
por: Yang, Xu, et al.
Publicado: (2021)

Genomic characterization of co-existing neoplasia and carcinoma lesions reveals distinct evolutionary paths of gallbladder cancer
por: Lin, Jianzhen, et al.
Publicado: (2021)

Construction and Investigation of a lncRNA-Associated ceRNA Regulatory Network in Cholangiocarcinoma
por: Long, Junyu, et al.
Publicado: (2019)

N6-methyladenosine associated prognostic model in hepatocellular carcinoma
por: Huang, Hanchun, et al.
Publicado: (2020)

Brain metastases from hepatocellular carcinoma: recent advances and future avenues
por: Wang, Shanshan, et al.
Publicado: (2017)

Gut microbiome is associated with the clinical response to anti-PD-1 based immunotherapy in hepatobiliary cancers
por: Mao, Jinzhu, et al.
Publicado: (2021)

Transcriptomic analysis and identification of prognostic biomarkers in cholangiocarcinoma
por: Li, Hanyu, et al.
Publicado: (2019)

Construction and Validation of Novel Diagnostic and Prognostic DNA Methylation Signatures for Hepatocellular Carcinoma
por: Li, Ran, et al.
Publicado: (2020)

Development and Validation of a Prognostic Nomogram for Gastric Cancer Based on DNA Methylation-Driven Differentially Expressed Genes
por: Bai, Yi, et al.
Publicado: (2020)

Identification and validation of the angiogenic genes for constructing diagnostic, prognostic, and recurrence models for hepatocellular carcinoma
por: Zhu, Jinyu, et al.
Publicado: (2020)

Development and validation of a selenium metabolism regulators associated prognostic model for hepatocellular carcinoma
por: Sun, Huishan, et al.
Publicado: (2023)

Gallbladder papillary neoplasms share pathological features with intraductal papillary neoplasm of the bile duct
por: Wan, Xueshuai, et al.
Publicado: (2017)

Unleashing The Potential Of Multiple-Targeted Therapies In Hepatobiliary Cancers: Two Cases, Cocktail Therapy With Nine Molecular Targeted Agents And Long-Lasting Survival
por: Lin, Jianzhen, et al.
Publicado: (2019)

Lenvatinib Beyond First-Line Therapy in Patients With Advanced Biliary Tract Carcinoma
por: Wang, Yunchao, et al.
Publicado: (2022)

Immunotherapy prototype Mark 3.0 model in primary liver cancer: adding locoregional stereotactic therapy and prognostic factors classification management
por: Yang, Xu, et al.
Publicado: (2023)

Identification of NOTCH4 mutation as a response biomarker for immune checkpoint inhibitor therapy
por: Long, Junyu, et al.
Publicado: (2021)

Mutational spectrum and precision oncology for biliary tract carcinoma
por: Lin, Jianzhen, et al.
Publicado: (2021)

Prognostic value and underlying mechanism of KIAA0101 in hepatocellular carcinoma: database mining and co-expression analysis
por: Xu, Weiyu, et al.
Publicado: (2020)

Construction and Validation of a Reliable Six-Gene Prognostic Signature Based on the TP53 Alteration for Hepatocellular Carcinoma
por: Huo, Junyu, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_sc13mip488d5tk3dqda94ao7d3